**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 76-year-old mam developed accelerated viral replication following an off-label treatment with methylprednisolone and prednisone for possible organising pneumonia \[*not all dosages and routes stated*\].

The man presented to a quaternary care hospital with fatigue, respiratory symptoms and a fainting episode for duration of 6 days. Three months prior to the presentation, he had a resolving post-infectious dry cough from an upper respiratory infection. His medical history was significant for gastritis, hypertension, sciatica, diabetes and a remote 30 pack-year smoking history. He had been receiving treatment with rosuvastatin and metformin. In early March, he had a potential exposure to a student with coronavirus disease 2019 (COVID-19). One week after the exposure and after 2 days of worsening cough, he underwent an outpatient nasopharyngeal swab for SARS-CoV-2 infection; however, the results were found to be negative. Over the next 4 days, he developed a worsening dry cough, exertional dyspnoea, fever, fatigue, diarrhoea and low appetite. After 4 days of his first swab test for SARS-CoV-2, he presented to the emergency department. He was then admitted to the hospital and placed under droplet and contact precautions. On admission, his initial vital signs revealed the following: BP 98/55mm Hg, body temperature 38.6°C, RR 18 breaths/minute, orthostatic drop, pulse rate 94 beats/minute and oxygen saturation of 96% on room air. A physical examination revealed flat neck veins. Additionally, he had mild inspiratory bibasilar crackles. Blood work revealed lymphopenia. Chest radiography revealed ill-defined right basal airspace opacification. He started receiving treatment with ceftriaxone and azithromycin for pneumonia. On admission, repeat nasopharyngeal swab for SARS CoV-2 infection was again found to be negative. On admission day 3, he became hypoxaemic and required 2 L/minute of oxygen. Repeat chest radiography revealed new bilateral, ill-defined patchy opacities. Subsequently, droplet and contact precautions were stopped on admission day 3. The chest CT revealed bilateral ground glass opacification and septal lines. A differential diagnosis of oedema, haemorrhage, drug reaction and connective tissue disease was made. On admission day 4, his hypoxaemia worsened and required 5 L/minute of oxygen. Consequently, droplet and contact precautions were restarted. His treatment with ceftriaxone and azithromycin was stopped, and he started receiving treatment with vancomycin and piperacillin/tazobactam. Additionally, he started receiving an off-label empirical treatment with IV methylprednisolone 125mg once daily along with prednisone for possible organising pneumonia. On admission day 4, sputum cultures and a fourth nasopharyngeal swab for SARS CoV-2 infection was again found to be negative. Therefore, he was transferred to the ICU. Subsequently, an unspecified diuretic was attempted and a fraction of inspired oxygen (FiO~2~) at 60% via a high-flow nasal canula was administered. On admission day 5, he required 90% of FiO~2~. Subsequently, he was intubated and ventilated using a lung protective strategy. His dosage of methylprednisolone was increased to 125mg every 6h. On admission day 6, bronchoscopy revealed bloody returns on sequential bronchoalveolar lavage. Real-time reverse transcriptase-polymerase chain reaction testing revealed a positive result for SARS-CoV-2 infection. On admission day 7, nasopharyngeal swab and tracheal aspirate testing showed positive results for SARS-CoV-2 infection. Accelerated viral replication secondary to methylprednisolone and prednisone was considered.

The man received supportive treatment and was extubated on admission day 10. Subsequently, his dose of prednisone was reduced to 50 mg/day, which was later tapered by 5mg every 3 days. On admission day 15, repeat CT showed segmental pulmonary embolism and evolving lung infiltrates. On admission day 19, he was discharged on therapeutic anticoagulation.
